Ascendis Pharma Stock Forecast

Stock Price Forecast

According to 20 analysts polled by S&P Global, Ascendis Pharma stock has a consensus rating of "Strong Buy" and an average price target of $305.28. The average 1-year stock price forecast is 35.46% higher than the current stock price, while the lowest is $261.51 (+16.04%) and the highest is $348.92 (+54.82%).

Price Target: $305.28 (+35.46%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$261.51	$305.28	$311.53	$348.92
Change	+16.04%	+35.46%	+38.23%	+54.82%

Analyst Ratings

The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	13	14	14	16	15	15
Buy	4	4	4	4	5	5
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	17	18	18	20	20	20

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Sean Laaman Morgan Stanley	Morgan Stanley	Buy Reiterates $273	Buy	Reiterates	$273	+21.13%	Oct 3, 2026
Eliana Merle Barclays	Barclays	Buy Maintains $329	Buy	Maintains	$329	+45.98%	Sep 30, 2026
Li Watsek Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $300	Buy	Maintains	$300	+33.11%	Sep 25, 2026
Yun Zhong Wedbush	Wedbush	Buy Maintains $327	Buy	Maintains	$327	+45.09%	Sep 16, 2026
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Reiterates $344	Buy	Reiterates	$344	+52.64%	Sep 16, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.37B

from 720.13M

90.32%

from 720.13M

Revenue Next Year

2.01B

from 1.37B

46.90%

from 1.37B

EPS This Year

12.79

from -

EPS Next Year

9.62

from 12.79

-24.82%

from 12.79

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Jan 1, 2023	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	7.78M	51.17M	266.72M	363.64M	720.13M	1.37B
Revenue Growth	11.87%	557.93%	421.20%	36.34%	98.03%	90.32%
Gross Profit	4.26M	39.04M	222.32M	319.38M	625.22M	1.26B
Gross Margin	54.71%	76.28%	83.36%	87.83%	86.82%	92.28%
Operating Income	-451.79M	-561.81M	-455.54M	-278.76M	-136.27M	396.05M
Net Income	-383.58M	-583.19M	-481.45M	-378.08M	-228.03M	965.53M
EPS	-	-	-	-	-	12.79
Forward PE	-	-	-	-	-	15.71
Free Cash Flow	-	-	-	-	45.41M	495.93M
No. Analysts	-	-	-	-	-	18

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	1.5B
Avg	1.4B
Low	1.3B

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	109.6%
Avg	90.3%
Low	84.4%

EPS Forecast

Chart

EPS	2026	2027	2028
High	18.69
Avg	12.79
Low	3.61

EPS Growth

Chart

EPS Growth	2027	2028
High	26.3%
Avg	-24.8%
Low	-51.1%